nodes	percent_of_prediction	percent_of_DWPC	metapath
Prasugrel—CYP3A4—bone cancer	0.724	1	CbGaD
Prasugrel—CYP2B6—Cisplatin—bone cancer	0.0544	0.329	CbGbCtD
Prasugrel—CYP2B6—Doxorubicin—bone cancer	0.0365	0.22	CbGbCtD
Prasugrel—ALB—Methotrexate—bone cancer	0.0346	0.209	CbGbCtD
Prasugrel—CYP2C9—Cisplatin—bone cancer	0.0287	0.174	CbGbCtD
Prasugrel—CYP3A4—Doxorubicin—bone cancer	0.0112	0.0677	CbGbCtD
Prasugrel—CES2—Irinotecan Pathway—CYP3A4—bone cancer	0.00677	0.12	CbGpPWpGaD
Prasugrel—CES2—Fluoropyrimidine Activity—DHFR—bone cancer	0.00402	0.071	CbGpPWpGaD
Prasugrel—Clopidogrel—CYP3A4—bone cancer	0.00377	1	CrCbGaD
Prasugrel—P2RY12—Signal amplification—GNA11—bone cancer	0.00229	0.0405	CbGpPWpGaD
Prasugrel—CES2—E2F transcription factor network—DHFR—bone cancer	0.00213	0.0376	CbGpPWpGaD
Prasugrel—CYP2B6—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.0018	0.0318	CbGpPWpGaD
Prasugrel—CYP2B6—Liver X Receptor Pathway—CYP3A4—bone cancer	0.00152	0.0268	CbGpPWpGaD
Prasugrel—Pericardial effusion—Methotrexate—bone cancer	0.00143	0.0283	CcSEcCtD
Prasugrel—Haematochezia—Epirubicin—bone cancer	0.00137	0.027	CcSEcCtD
Prasugrel—CYP2C19—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00136	0.0241	CbGpPWpGaD
Prasugrel—Pericardial effusion—Epirubicin—bone cancer	0.00134	0.0265	CcSEcCtD
Prasugrel—Haematochezia—Doxorubicin—bone cancer	0.00126	0.025	CcSEcCtD
Prasugrel—CYP2C9—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00124	0.0219	CbGpPWpGaD
Prasugrel—Pericardial effusion—Doxorubicin—bone cancer	0.00124	0.0245	CcSEcCtD
Prasugrel—ALB—Folate Metabolism—FOLR1—bone cancer	0.00121	0.0214	CbGpPWpGaD
Prasugrel—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—bone cancer	0.00119	0.021	CbGpPWpGaD
Prasugrel—CES2—E2F transcription factor network—PLAU—bone cancer	0.00119	0.0209	CbGpPWpGaD
Prasugrel—Body temperature increased—Carboplatin—bone cancer	0.00103	0.0203	CcSEcCtD
Prasugrel—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000975	0.0172	CbGpPWpGaD
Prasugrel—CES2—E2F transcription factor network—RB1—bone cancer	0.000974	0.0172	CbGpPWpGaD
Prasugrel—Gingival bleeding—Epirubicin—bone cancer	0.00097	0.0192	CcSEcCtD
Prasugrel—CES2—Fluoropyrimidine Activity—TP53—bone cancer	0.000899	0.0159	CbGpPWpGaD
Prasugrel—Gingival bleeding—Doxorubicin—bone cancer	0.000897	0.0177	CcSEcCtD
Prasugrel—CES2—NRF2 pathway—TGFBR2—bone cancer	0.000888	0.0157	CbGpPWpGaD
Prasugrel—CES2—NRF2 pathway—GSTP1—bone cancer	0.000888	0.0157	CbGpPWpGaD
Prasugrel—CYP2B6—Xenobiotics—CYP3A4—bone cancer	0.000871	0.0154	CbGpPWpGaD
Prasugrel—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00082	0.0145	CbGpPWpGaD
Prasugrel—P2RY12—G alpha (i) signalling events—RGS1—bone cancer	0.000812	0.0143	CbGpPWpGaD
Prasugrel—P2RY12—G alpha (i) signalling events—GRM4—bone cancer	0.000812	0.0143	CbGpPWpGaD
Prasugrel—Cerebrovascular accident—Cisplatin—bone cancer	0.000794	0.0157	CcSEcCtD
Prasugrel—Gastrointestinal haemorrhage—Cisplatin—bone cancer	0.000778	0.0154	CcSEcCtD
Prasugrel—CYP2B6—Metapathway biotransformation—CYP4V2—bone cancer	0.000777	0.0137	CbGpPWpGaD
Prasugrel—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000771	0.0136	CbGpPWpGaD
Prasugrel—Hyperlipidaemia—Epirubicin—bone cancer	0.000764	0.0151	CcSEcCtD
Prasugrel—Haemoptysis—Epirubicin—bone cancer	0.000744	0.0147	CcSEcCtD
Prasugrel—Hyperlipidaemia—Doxorubicin—bone cancer	0.000706	0.014	CcSEcCtD
Prasugrel—Haemoptysis—Doxorubicin—bone cancer	0.000688	0.0136	CcSEcCtD
Prasugrel—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000672	0.0119	CbGpPWpGaD
Prasugrel—CYP2C19—Xenobiotics—CYP3A4—bone cancer	0.000658	0.0116	CbGpPWpGaD
Prasugrel—Neoplasm malignant—Epirubicin—bone cancer	0.000645	0.0127	CcSEcCtD
Prasugrel—CYP2C19—Tamoxifen metabolism—CYP3A4—bone cancer	0.000633	0.0112	CbGpPWpGaD
Prasugrel—Rectal haemorrhage—Epirubicin—bone cancer	0.000609	0.012	CcSEcCtD
Prasugrel—CYP2C9—Xenobiotics—CYP3A4—bone cancer	0.0006	0.0106	CbGpPWpGaD
Prasugrel—CYP2B6—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000598	0.0106	CbGpPWpGaD
Prasugrel—Neoplasm malignant—Doxorubicin—bone cancer	0.000596	0.0118	CcSEcCtD
Prasugrel—CYP2C19—Metapathway biotransformation—CYP4V2—bone cancer	0.000587	0.0104	CbGpPWpGaD
Prasugrel—CYP2C9—Tamoxifen metabolism—CYP3A4—bone cancer	0.000577	0.0102	CbGpPWpGaD
Prasugrel—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.00057	0.0101	CbGpPWpGaD
Prasugrel—Rectal haemorrhage—Doxorubicin—bone cancer	0.000564	0.0111	CcSEcCtD
Prasugrel—Bradycardia—Cisplatin—bone cancer	0.000548	0.0108	CcSEcCtD
Prasugrel—CYP2C9—Metapathway biotransformation—CYP4V2—bone cancer	0.000535	0.00944	CbGpPWpGaD
Prasugrel—Ecchymosis—Methotrexate—bone cancer	0.000532	0.0105	CcSEcCtD
Prasugrel—Neoplasm—Methotrexate—bone cancer	0.000532	0.0105	CcSEcCtD
Prasugrel—Urinary tract disorder—Cisplatin—bone cancer	0.000531	0.0105	CcSEcCtD
Prasugrel—Urethral disorder—Cisplatin—bone cancer	0.000528	0.0104	CcSEcCtD
Prasugrel—P2RY12—Platelet activation, signaling and aggregation—SPARC—bone cancer	0.000521	0.0092	CbGpPWpGaD
Prasugrel—Eye disorder—Cisplatin—bone cancer	0.000503	0.00993	CcSEcCtD
Prasugrel—ALB—Binding and Uptake of Ligands by Scavenger Receptors—SPARC—bone cancer	0.000498	0.00879	CbGpPWpGaD
Prasugrel—Ecchymosis—Epirubicin—bone cancer	0.000498	0.00983	CcSEcCtD
Prasugrel—Neoplasm—Epirubicin—bone cancer	0.000498	0.00983	CcSEcCtD
Prasugrel—P2RY12—GPCR ligand binding—GRM4—bone cancer	0.000492	0.00868	CbGpPWpGaD
Prasugrel—Immune system disorder—Cisplatin—bone cancer	0.000486	0.0096	CcSEcCtD
Prasugrel—Mediastinal disorder—Cisplatin—bone cancer	0.000485	0.00958	CcSEcCtD
Prasugrel—P2RY12—Platelet activation, signaling and aggregation—GNA11—bone cancer	0.000477	0.00841	CbGpPWpGaD
Prasugrel—Neoplasm—Doxorubicin—bone cancer	0.00046	0.00909	CcSEcCtD
Prasugrel—Ecchymosis—Doxorubicin—bone cancer	0.00046	0.00909	CcSEcCtD
Prasugrel—CYP2C19—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000452	0.00797	CbGpPWpGaD
Prasugrel—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000443	0.00782	CbGpPWpGaD
Prasugrel—Cerebrovascular accident—Methotrexate—bone cancer	0.000436	0.0086	CcSEcCtD
Prasugrel—Anaemia—Cisplatin—bone cancer	0.000433	0.00855	CcSEcCtD
Prasugrel—P2RY12—Platelet activation, signaling and aggregation—IL3—bone cancer	0.000432	0.00763	CbGpPWpGaD
Prasugrel—P2RY12—GPCR ligand binding—GRM1—bone cancer	0.000426	0.00753	CbGpPWpGaD
Prasugrel—Leukopenia—Cisplatin—bone cancer	0.000419	0.00828	CcSEcCtD
Prasugrel—CYP2C9—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000412	0.00727	CbGpPWpGaD
Prasugrel—Cerebrovascular accident—Epirubicin—bone cancer	0.000408	0.00805	CcSEcCtD
Prasugrel—Gastrointestinal haemorrhage—Epirubicin—bone cancer	0.0004	0.00789	CcSEcCtD
Prasugrel—Pain in extremity—Epirubicin—bone cancer	0.0004	0.00789	CcSEcCtD
Prasugrel—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.000396	0.00782	CcSEcCtD
Prasugrel—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000392	0.00693	CbGpPWpGaD
Prasugrel—Anaphylactic shock—Cisplatin—bone cancer	0.000382	0.00755	CcSEcCtD
Prasugrel—Cerebrovascular accident—Doxorubicin—bone cancer	0.000377	0.00745	CcSEcCtD
Prasugrel—Thrombocytopenia—Cisplatin—bone cancer	0.000374	0.00739	CcSEcCtD
Prasugrel—Skin disorder—Cisplatin—bone cancer	0.000371	0.00733	CcSEcCtD
Prasugrel—Gastrointestinal haemorrhage—Doxorubicin—bone cancer	0.00037	0.0073	CcSEcCtD
Prasugrel—Pain in extremity—Doxorubicin—bone cancer	0.00037	0.0073	CcSEcCtD
Prasugrel—CYP2B6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000362	0.00638	CbGpPWpGaD
Prasugrel—Hypotension—Cisplatin—bone cancer	0.000357	0.00706	CcSEcCtD
Prasugrel—CYP2B6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000357	0.0063	CbGpPWpGaD
Prasugrel—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.000353	0.00623	CbGpPWpGaD
Prasugrel—Dyspnoea—Cisplatin—bone cancer	0.000341	0.00673	CcSEcCtD
Prasugrel—ALB—Folate Metabolism—DHFR—bone cancer	0.000333	0.00587	CbGpPWpGaD
Prasugrel—Gastrointestinal disorder—Cisplatin—bone cancer	0.00033	0.00652	CcSEcCtD
Prasugrel—Haematuria—Methotrexate—bone cancer	0.000314	0.00619	CcSEcCtD
Prasugrel—Epistaxis—Methotrexate—bone cancer	0.00031	0.00613	CcSEcCtD
Prasugrel—Body temperature increased—Cisplatin—bone cancer	0.000302	0.00597	CcSEcCtD
Prasugrel—P2RY12—GPCR ligand binding—SMO—bone cancer	0.0003	0.0053	CbGpPWpGaD
Prasugrel—Haemoglobin—Methotrexate—bone cancer	0.000297	0.00586	CcSEcCtD
Prasugrel—Haemorrhage—Methotrexate—bone cancer	0.000295	0.00583	CcSEcCtD
Prasugrel—Haematuria—Epirubicin—bone cancer	0.000294	0.0058	CcSEcCtD
Prasugrel—CYP2B6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000293	0.00517	CbGpPWpGaD
Prasugrel—Urinary tract disorder—Methotrexate—bone cancer	0.000292	0.00576	CcSEcCtD
Prasugrel—ALB—Platelet degranulation—SPARC—bone cancer	0.000292	0.00515	CbGpPWpGaD
Prasugrel—Epistaxis—Epirubicin—bone cancer	0.00029	0.00573	CcSEcCtD
Prasugrel—Urethral disorder—Methotrexate—bone cancer	0.000289	0.00572	CcSEcCtD
Prasugrel—Hypersensitivity—Cisplatin—bone cancer	0.000282	0.00556	CcSEcCtD
Prasugrel—Bradycardia—Epirubicin—bone cancer	0.000281	0.00556	CcSEcCtD
Prasugrel—P2RY12—GPCR downstream signaling—RGS1—bone cancer	0.000278	0.0049	CbGpPWpGaD
Prasugrel—P2RY12—GPCR downstream signaling—GRM4—bone cancer	0.000278	0.0049	CbGpPWpGaD
Prasugrel—ALB—Response to elevated platelet cytosolic Ca2+—SPARC—bone cancer	0.000278	0.0049	CbGpPWpGaD
Prasugrel—Haemoglobin—Epirubicin—bone cancer	0.000278	0.00549	CcSEcCtD
Prasugrel—Haemorrhage—Epirubicin—bone cancer	0.000276	0.00546	CcSEcCtD
Prasugrel—Eye disorder—Methotrexate—bone cancer	0.000276	0.00545	CcSEcCtD
Prasugrel—Asthenia—Cisplatin—bone cancer	0.000274	0.00542	CcSEcCtD
Prasugrel—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000273	0.00482	CbGpPWpGaD
Prasugrel—Urinary tract disorder—Epirubicin—bone cancer	0.000273	0.00539	CcSEcCtD
Prasugrel—Oedema peripheral—Epirubicin—bone cancer	0.000272	0.00538	CcSEcCtD
Prasugrel—Haematuria—Doxorubicin—bone cancer	0.000272	0.00536	CcSEcCtD
Prasugrel—Urethral disorder—Epirubicin—bone cancer	0.000271	0.00535	CcSEcCtD
Prasugrel—CYP2C19—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.00027	0.00476	CbGpPWpGaD
Prasugrel—Epistaxis—Doxorubicin—bone cancer	0.000269	0.00531	CcSEcCtD
Prasugrel—P2RY12—Hemostasis—SPARC—bone cancer	0.000269	0.00474	CbGpPWpGaD
Prasugrel—Angiopathy—Methotrexate—bone cancer	0.000268	0.00529	CcSEcCtD
Prasugrel—Immune system disorder—Methotrexate—bone cancer	0.000267	0.00527	CcSEcCtD
Prasugrel—Mediastinal disorder—Methotrexate—bone cancer	0.000266	0.00526	CcSEcCtD
Prasugrel—Diarrhoea—Cisplatin—bone cancer	0.000262	0.00517	CcSEcCtD
Prasugrel—Bradycardia—Doxorubicin—bone cancer	0.00026	0.00514	CcSEcCtD
Prasugrel—Eye disorder—Epirubicin—bone cancer	0.000258	0.0051	CcSEcCtD
Prasugrel—Haemoglobin—Doxorubicin—bone cancer	0.000257	0.00508	CcSEcCtD
Prasugrel—Haemorrhage—Doxorubicin—bone cancer	0.000256	0.00505	CcSEcCtD
Prasugrel—Urinary tract disorder—Doxorubicin—bone cancer	0.000253	0.00499	CcSEcCtD
Prasugrel—P2RY12—Signaling by GPCR—RGS1—bone cancer	0.000252	0.00445	CbGpPWpGaD
Prasugrel—P2RY12—Signaling by GPCR—GRM4—bone cancer	0.000252	0.00445	CbGpPWpGaD
Prasugrel—Oedema peripheral—Doxorubicin—bone cancer	0.000252	0.00497	CcSEcCtD
Prasugrel—Angiopathy—Epirubicin—bone cancer	0.000251	0.00495	CcSEcCtD
Prasugrel—Urethral disorder—Doxorubicin—bone cancer	0.000251	0.00495	CcSEcCtD
Prasugrel—Immune system disorder—Epirubicin—bone cancer	0.00025	0.00493	CcSEcCtD
Prasugrel—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000249	0.0044	CbGpPWpGaD
Prasugrel—Mediastinal disorder—Epirubicin—bone cancer	0.000249	0.00492	CcSEcCtD
Prasugrel—Back pain—Methotrexate—bone cancer	0.000249	0.00491	CcSEcCtD
Prasugrel—CYP2C9—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000246	0.00434	CbGpPWpGaD
Prasugrel—P2RY12—Hemostasis—GNA11—bone cancer	0.000246	0.00434	CbGpPWpGaD
Prasugrel—Rash—Cisplatin—bone cancer	0.000241	0.00476	CcSEcCtD
Prasugrel—P2RY12—GPCR downstream signaling—GRM1—bone cancer	0.000241	0.00425	CbGpPWpGaD
Prasugrel—Dermatitis—Cisplatin—bone cancer	0.000241	0.00476	CcSEcCtD
Prasugrel—Eye disorder—Doxorubicin—bone cancer	0.000239	0.00472	CcSEcCtD
Prasugrel—Anaemia—Methotrexate—bone cancer	0.000238	0.00469	CcSEcCtD
Prasugrel—Back pain—Epirubicin—bone cancer	0.000233	0.0046	CcSEcCtD
Prasugrel—Angiopathy—Doxorubicin—bone cancer	0.000232	0.00458	CcSEcCtD
Prasugrel—Immune system disorder—Doxorubicin—bone cancer	0.000231	0.00456	CcSEcCtD
Prasugrel—Mediastinal disorder—Doxorubicin—bone cancer	0.00023	0.00455	CcSEcCtD
Prasugrel—Leukopenia—Methotrexate—bone cancer	0.00023	0.00454	CcSEcCtD
Prasugrel—Nausea—Cisplatin—bone cancer	0.000227	0.00448	CcSEcCtD
Prasugrel—Cough—Methotrexate—bone cancer	0.000224	0.00443	CcSEcCtD
Prasugrel—P2RY12—Hemostasis—IL3—bone cancer	0.000223	0.00393	CbGpPWpGaD
Prasugrel—Anaemia—Epirubicin—bone cancer	0.000222	0.00439	CcSEcCtD
Prasugrel—CYP2C19—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000222	0.00391	CbGpPWpGaD
Prasugrel—P2RY12—Signaling by GPCR—GRM1—bone cancer	0.000219	0.00386	CbGpPWpGaD
Prasugrel—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000217	0.00429	CcSEcCtD
Prasugrel—Leukopenia—Epirubicin—bone cancer	0.000215	0.00425	CcSEcCtD
Prasugrel—Back pain—Doxorubicin—bone cancer	0.000215	0.00425	CcSEcCtD
Prasugrel—Cough—Epirubicin—bone cancer	0.00021	0.00415	CcSEcCtD
Prasugrel—Anaphylactic shock—Methotrexate—bone cancer	0.00021	0.00414	CcSEcCtD
Prasugrel—Hypertension—Epirubicin—bone cancer	0.000208	0.0041	CcSEcCtD
Prasugrel—Anaemia—Doxorubicin—bone cancer	0.000206	0.00406	CcSEcCtD
Prasugrel—Thrombocytopenia—Methotrexate—bone cancer	0.000205	0.00406	CcSEcCtD
Prasugrel—Skin disorder—Methotrexate—bone cancer	0.000204	0.00402	CcSEcCtD
Prasugrel—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000203	0.00402	CcSEcCtD
Prasugrel—CYP2C9—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000202	0.00356	CbGpPWpGaD
Prasugrel—Leukopenia—Doxorubicin—bone cancer	0.000199	0.00393	CcSEcCtD
Prasugrel—Anaphylactic shock—Epirubicin—bone cancer	0.000196	0.00388	CcSEcCtD
Prasugrel—Hypotension—Methotrexate—bone cancer	0.000196	0.00387	CcSEcCtD
Prasugrel—Cough—Doxorubicin—bone cancer	0.000194	0.00384	CcSEcCtD
Prasugrel—Thrombocytopenia—Epirubicin—bone cancer	0.000192	0.0038	CcSEcCtD
Prasugrel—Hypertension—Doxorubicin—bone cancer	0.000192	0.0038	CcSEcCtD
Prasugrel—Skin disorder—Epirubicin—bone cancer	0.000191	0.00377	CcSEcCtD
Prasugrel—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000188	0.00372	CcSEcCtD
Prasugrel—Dyspnoea—Methotrexate—bone cancer	0.000187	0.00369	CcSEcCtD
Prasugrel—Hypotension—Epirubicin—bone cancer	0.000183	0.00362	CcSEcCtD
Prasugrel—Anaphylactic shock—Doxorubicin—bone cancer	0.000182	0.00359	CcSEcCtD
Prasugrel—Gastrointestinal disorder—Methotrexate—bone cancer	0.000181	0.00358	CcSEcCtD
Prasugrel—Fatigue—Methotrexate—bone cancer	0.000181	0.00357	CcSEcCtD
Prasugrel—Thrombocytopenia—Doxorubicin—bone cancer	0.000178	0.00351	CcSEcCtD
Prasugrel—Skin disorder—Doxorubicin—bone cancer	0.000176	0.00348	CcSEcCtD
Prasugrel—Dyspnoea—Epirubicin—bone cancer	0.000175	0.00346	CcSEcCtD
Prasugrel—Hypotension—Doxorubicin—bone cancer	0.00017	0.00335	CcSEcCtD
Prasugrel—Gastrointestinal disorder—Epirubicin—bone cancer	0.00017	0.00335	CcSEcCtD
Prasugrel—Fatigue—Epirubicin—bone cancer	0.000169	0.00334	CcSEcCtD
Prasugrel—Body temperature increased—Methotrexate—bone cancer	0.000166	0.00328	CcSEcCtD
Prasugrel—Dyspnoea—Doxorubicin—bone cancer	0.000162	0.0032	CcSEcCtD
Prasugrel—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000157	0.0031	CcSEcCtD
Prasugrel—Fatigue—Doxorubicin—bone cancer	0.000157	0.00309	CcSEcCtD
Prasugrel—CYP2B6—Biological oxidations—CYP3A4—bone cancer	0.000156	0.00275	CbGpPWpGaD
Prasugrel—P2RY12—GPCR downstream signaling—GNA11—bone cancer	0.000155	0.00274	CbGpPWpGaD
Prasugrel—Body temperature increased—Epirubicin—bone cancer	0.000155	0.00307	CcSEcCtD
Prasugrel—Hypersensitivity—Methotrexate—bone cancer	0.000155	0.00305	CcSEcCtD
Prasugrel—P2RY12—Signaling by GPCR—SMO—bone cancer	0.000154	0.00272	CbGpPWpGaD
Prasugrel—CYP2B6—Metapathway biotransformation—CYP3A4—bone cancer	0.000154	0.00271	CbGpPWpGaD
Prasugrel—Asthenia—Methotrexate—bone cancer	0.000151	0.00297	CcSEcCtD
Prasugrel—P2RY12—Signaling Pathways—GRM4—bone cancer	0.000149	0.00263	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—RGS1—bone cancer	0.000149	0.00263	CbGpPWpGaD
Prasugrel—P2RY12—Hemostasis—PLAU—bone cancer	0.000146	0.00258	CbGpPWpGaD
Prasugrel—Hypersensitivity—Epirubicin—bone cancer	0.000145	0.00286	CcSEcCtD
Prasugrel—Body temperature increased—Doxorubicin—bone cancer	0.000144	0.00284	CcSEcCtD
Prasugrel—Diarrhoea—Methotrexate—bone cancer	0.000144	0.00283	CcSEcCtD
Prasugrel—P2RY12—Signaling by GPCR—GNA11—bone cancer	0.000141	0.00249	CbGpPWpGaD
Prasugrel—Asthenia—Epirubicin—bone cancer	0.000141	0.00278	CcSEcCtD
Prasugrel—P2RY12—GPCR downstream signaling—IL3—bone cancer	0.000141	0.00248	CbGpPWpGaD
Prasugrel—CYP2C19—Arachidonic acid metabolism—PTGS2—bone cancer	0.00014	0.00247	CbGpPWpGaD
Prasugrel—Dizziness—Methotrexate—bone cancer	0.000139	0.00274	CcSEcCtD
Prasugrel—Diarrhoea—Epirubicin—bone cancer	0.000134	0.00265	CcSEcCtD
Prasugrel—Hypersensitivity—Doxorubicin—bone cancer	0.000134	0.00264	CcSEcCtD
Prasugrel—CYP2B6—Biological oxidations—GSTP1—bone cancer	0.000133	0.00235	CbGpPWpGaD
Prasugrel—Rash—Methotrexate—bone cancer	0.000132	0.00261	CcSEcCtD
Prasugrel—Dermatitis—Methotrexate—bone cancer	0.000132	0.00261	CcSEcCtD
Prasugrel—Headache—Methotrexate—bone cancer	0.000131	0.0026	CcSEcCtD
Prasugrel—CYP2B6—Metapathway biotransformation—GSTP1—bone cancer	0.000131	0.00232	CbGpPWpGaD
Prasugrel—Asthenia—Doxorubicin—bone cancer	0.00013	0.00257	CcSEcCtD
Prasugrel—Dizziness—Epirubicin—bone cancer	0.00013	0.00256	CcSEcCtD
Prasugrel—ALB—Platelet activation, signaling and aggregation—SPARC—bone cancer	0.000129	0.00228	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—GRM1—bone cancer	0.000129	0.00228	CbGpPWpGaD
Prasugrel—P2RY12—Signaling by GPCR—IL3—bone cancer	0.000128	0.00226	CbGpPWpGaD
Prasugrel—CYP2C9—Arachidonic acid metabolism—PTGS2—bone cancer	0.000128	0.00225	CbGpPWpGaD
Prasugrel—Nausea—Methotrexate—bone cancer	0.000125	0.00246	CcSEcCtD
Prasugrel—Diarrhoea—Doxorubicin—bone cancer	0.000124	0.00245	CcSEcCtD
Prasugrel—Rash—Epirubicin—bone cancer	0.000124	0.00244	CcSEcCtD
Prasugrel—Dermatitis—Epirubicin—bone cancer	0.000124	0.00244	CcSEcCtD
Prasugrel—Headache—Epirubicin—bone cancer	0.000123	0.00243	CcSEcCtD
Prasugrel—Dizziness—Doxorubicin—bone cancer	0.00012	0.00237	CcSEcCtD
Prasugrel—ALB—Platelet activation, signaling and aggregation—GNA11—bone cancer	0.000118	0.00209	CbGpPWpGaD
Prasugrel—CYP2C19—Biological oxidations—CYP3A4—bone cancer	0.000118	0.00208	CbGpPWpGaD
Prasugrel—Nausea—Epirubicin—bone cancer	0.000117	0.0023	CcSEcCtD
Prasugrel—CYP2C19—Metapathway biotransformation—CYP3A4—bone cancer	0.000116	0.00205	CbGpPWpGaD
Prasugrel—Rash—Doxorubicin—bone cancer	0.000115	0.00226	CcSEcCtD
Prasugrel—Dermatitis—Doxorubicin—bone cancer	0.000114	0.00226	CcSEcCtD
Prasugrel—Headache—Doxorubicin—bone cancer	0.000114	0.00225	CcSEcCtD
Prasugrel—Nausea—Doxorubicin—bone cancer	0.000108	0.00213	CcSEcCtD
Prasugrel—CYP2C9—Biological oxidations—CYP3A4—bone cancer	0.000107	0.00189	CbGpPWpGaD
Prasugrel—ALB—Platelet activation, signaling and aggregation—IL3—bone cancer	0.000107	0.00189	CbGpPWpGaD
Prasugrel—CYP2C9—Metapathway biotransformation—CYP3A4—bone cancer	0.000106	0.00187	CbGpPWpGaD
Prasugrel—CYP2C19—Biological oxidations—GSTP1—bone cancer	0.000101	0.00178	CbGpPWpGaD
Prasugrel—ALB—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000101	0.00177	CbGpPWpGaD
Prasugrel—ALB—Selenium Micronutrient Network—PTGS2—bone cancer	9.93e-05	0.00175	CbGpPWpGaD
Prasugrel—CYP2C19—Metapathway biotransformation—GSTP1—bone cancer	9.93e-05	0.00175	CbGpPWpGaD
Prasugrel—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	9.34e-05	0.00165	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—NDUFA12—bone cancer	9.33e-05	0.00165	CbGpPWpGaD
Prasugrel—CYP2C9—Biological oxidations—GSTP1—bone cancer	9.18e-05	0.00162	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—SMO—bone cancer	9.11e-05	0.00161	CbGpPWpGaD
Prasugrel—CYP2C9—Metapathway biotransformation—GSTP1—bone cancer	9.05e-05	0.0016	CbGpPWpGaD
Prasugrel—ALB—Transmembrane transport of small molecules—TUBB2A—bone cancer	8.68e-05	0.00153	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—GNA11—bone cancer	8.33e-05	0.00147	CbGpPWpGaD
Prasugrel—ALB—Metabolism—NDUFA12—bone cancer	7.86e-05	0.00139	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—ATF1—bone cancer	7.74e-05	0.00137	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—NT5C3A—bone cancer	7.73e-05	0.00137	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—IL3—bone cancer	7.55e-05	0.00133	CbGpPWpGaD
Prasugrel—ALB—Folate Metabolism—TP53—bone cancer	7.44e-05	0.00131	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—NDUFA12—bone cancer	7.05e-05	0.00124	CbGpPWpGaD
Prasugrel—ALB—Hemostasis—SPARC—bone cancer	6.67e-05	0.00118	CbGpPWpGaD
Prasugrel—ALB—Metabolism—NT5C3A—bone cancer	6.51e-05	0.00115	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—TGFBR2—bone cancer	6.46e-05	0.00114	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—NDUFA12—bone cancer	6.43e-05	0.00114	CbGpPWpGaD
Prasugrel—ALB—Hemostasis—GNA11—bone cancer	6.1e-05	0.00108	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—IGF1R—bone cancer	6.08e-05	0.00107	CbGpPWpGaD
Prasugrel—CYP3A4—Biological oxidations—GSTP1—bone cancer	6.05e-05	0.00107	CbGpPWpGaD
Prasugrel—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	5.97e-05	0.00105	CbGpPWpGaD
Prasugrel—P2RY12—Hemostasis—TP53—bone cancer	5.87e-05	0.00104	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—NT5C3A—bone cancer	5.84e-05	0.00103	CbGpPWpGaD
Prasugrel—ALB—Hemostasis—IL3—bone cancer	5.53e-05	0.000976	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—NT5C3A—bone cancer	5.33e-05	0.000941	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—KIT—bone cancer	4.41e-05	0.000778	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—NDUFA12—bone cancer	4.24e-05	0.000749	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—BRAF—bone cancer	4.14e-05	0.000731	CbGpPWpGaD
Prasugrel—P2RY12—Signaling by GPCR—EGFR—bone cancer	4.02e-05	0.000709	CbGpPWpGaD
Prasugrel—ALB—Hemostasis—PLAU—bone cancer	3.63e-05	0.00064	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—NT5C3A—bone cancer	3.51e-05	0.00062	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—MDM2—bone cancer	3.47e-05	0.000613	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—ENO2—bone cancer	3.39e-05	0.000598	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—DHFR—bone cancer	3.14e-05	0.000555	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—JUN—bone cancer	3.02e-05	0.000532	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—GNA11—bone cancer	2.94e-05	0.000518	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—MMP9—bone cancer	2.94e-05	0.000518	CbGpPWpGaD
Prasugrel—ALB—Metabolism—ENO2—bone cancer	2.85e-05	0.000503	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—CYP3A4—bone cancer	2.66e-05	0.00047	CbGpPWpGaD
Prasugrel—ALB—Metabolism—DHFR—bone cancer	2.65e-05	0.000467	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—ENO2—bone cancer	2.56e-05	0.000452	CbGpPWpGaD
Prasugrel—ALB—Metabolism—GNA11—bone cancer	2.47e-05	0.000436	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—DHFR—bone cancer	2.38e-05	0.000419	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—EGFR—bone cancer	2.37e-05	0.000419	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—ENO2—bone cancer	2.33e-05	0.000412	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—GSTP1—bone cancer	2.28e-05	0.000402	CbGpPWpGaD
Prasugrel—ALB—Metabolism—CYP3A4—bone cancer	2.24e-05	0.000396	CbGpPWpGaD
Prasugrel—ALB—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.23e-05	0.000394	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—GNA11—bone cancer	2.22e-05	0.000392	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—DHFR—bone cancer	2.17e-05	0.000382	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—GNA11—bone cancer	2.02e-05	0.000357	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—CYP3A4—bone cancer	2.01e-05	0.000355	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2e-05	0.000353	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—TP53—bone cancer	1.99e-05	0.000351	CbGpPWpGaD
Prasugrel—ALB—Metabolism—GSTP1—bone cancer	1.92e-05	0.000338	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—CYP3A4—bone cancer	1.83e-05	0.000324	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.83e-05	0.000322	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—GSTP1—bone cancer	1.72e-05	0.000304	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—GSTP1—bone cancer	1.57e-05	0.000277	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—ENO2—bone cancer	1.54e-05	0.000272	CbGpPWpGaD
Prasugrel—ALB—Hemostasis—TP53—bone cancer	1.46e-05	0.000257	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—DHFR—bone cancer	1.43e-05	0.000252	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—GNA11—bone cancer	1.33e-05	0.000236	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—PTGS2—bone cancer	1.18e-05	0.000208	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—GSTP1—bone cancer	1.04e-05	0.000183	CbGpPWpGaD
Prasugrel—ALB—Metabolism—PTGS2—bone cancer	9.93e-06	0.000175	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—PTGS2—bone cancer	8.92e-06	0.000157	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—PTGS2—bone cancer	8.13e-06	0.000143	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—PTGS2—bone cancer	5.36e-06	9.46e-05	CbGpPWpGaD
